STOCK TITAN
  1. Home
  2. News
  3. KRTX

Karuna Therapeutics to Participate in the ICR Conference 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that Andrew Miller, Ph.D., chief operating officer and founder, will participate in a fireside chat at the ICR Conference 2021 on Thursday, January 14, 2021 at 3:15 p.m. EST.

A live webcast of the presentation will be available on the Investor Relations page of Karuna’s website at investors.karunatx.com. A replay of the webcast will also be archived for up to 90 days on Karuna’s website following the conference.

About Karuna Therapeutics
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples’ lives. For more information, please visit www.karunatx.com.

Stock KRTX logo
Karuna Therapeutics, Inc.

NASDAQ:KRTX

KRTX Rankings

N/A Ranked by Market Cap
#3616 Ranked by Stock Gains
N/A Ranked by Dividends

KRTX Latest News

Feb 22, 2024
Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
Dec 22, 2023
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Dec 22, 2023
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Dec 22, 2023
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Dec 14, 2023
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

KRTX Stock Data

12.60B
36.27M
4.99%
86.32%
5.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About KRTX

we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip